Purchase this article with an account.
Y. Saito, D.J. Martiniuk, P. Geisen, W. Smith, L.J. Peterson, J.R. McColm, M.E. Hartnett; Effects of Intraocular Injections of Antibody to Vascular Endothelial Growth Factor Isoform 164 on Oxygen–Induced Retinopathy in Neonatal Rats . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5316.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate intraocular injections of antibody to VEGF164 on oxygen–induced retinopathy (OIR) in rats.
Newborn rat pups were exposed to cycles of 24 h of 50% oxygen and 24 h of 10% oxygen. On p12 pups were randomly assigned to receive intraocular injections in their right eyes of either 25ng, 50ng, 100ng VEGF164 antibody (R&D Systems, MN) or PBS. The matched left eyes were non–injected. Animals were returned to the Oxycycler (Biospherix, NY) until p14 and then moved to room air until p18 when they were weighed and sacrificed. Retinas were dissected, flat mounted and stained with lectin. Clock hours of neovascularization (NV) were counted and avascular areas were expressed as a percent of total retinal area. Junctions of capillaries were counted as a measure of central capillary density. Data was analyzed using SPSS software.
There were two separate litters and body weights were not significantly different between them, or between pups, at p14 or p18. There were significant differences between treatment groups for clock hours and central capillary density (NV, ANOVA p=0.046; capillary density, ANOVA p=0.043). Total retinal areas and peripheral avascular areas were not significantly different between groups.
Intraocular injections of antibody to VEGF164 prevented pathological retinal neovascularization and reduced central capillary density. The total retinal areas and peripheral avascular areas were not affected. These data confirm that VEGF164 is an important promoter of intravitreous retinal neovascularization.
This PDF is available to Subscribers Only